Introduction
In a 2007 survey of public health officials in the United States, International Society for Disease Surveillance found that only 7% used pharmacy prescription sales data for surveillance (1) . There have been many reports suggesting effective use of prescription sales data in syndromic surveillance (2, 3, 4, 5). Community pharmacies can provide a valuable supplementary tool for syndromic surveillance of infectious diseases.
Methods
We extracted five years of de-identified prescription sales data from the proprietary pharmacy computer system of a large retail pharmacy chain in the United States. The prescriptions were written for the common drugs for the treatment of influenza: Amantadine, Oseltamivir, Rimantadine, and Zanamivir. We acquired Google Flu trends national aggregate counts data that represented the estimates of the ILI cases per 100,000 physician visits. We acquired CDC ILINET data for 2007. We calculated Pearson 'r' between our data and Google and CDC data. We also created comparable trends graphs after converting the counts of the influenza scripts and the counts of the Google estimated ILI cases to logarithmic scale.
Results
The Pearson 'r' between the aggregate counts of scripts for all the four drugs and the Google estimates of the ILI cases for years 2007 
Conclusions
A strong to very strong correlation between prescription sales data and Google Flu trends and CDC's ILI activities data for influenza suggests that the former can serve as a good and valid influenza activity indicator. Community pharmacies with large footprints might want to proactively build automated syndromic surveillance systems with near real time reporting capabilities and explore the possibility of building predictive models (3) and of forming partnerships with public health agencies for syndromic surveillance.
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